Cancer News and Research

Latest Cancer News and Research

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Presentations at Tuesday's RSNA conference

A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.

30 Nov 2009

Medipattern, Sentinelle Medical sign technology access and distribution agreement

The Medipattern Corporation (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity and Sentinelle Medical Inc., a leading manufacturer of magnetic resonance imaging (MRI) coils and advanced visualization software, have announced that they are entering a technology access and distribution agreement.

30 Nov 2009

Sentinelle Medical, Siemens Healthcare to jointly develop solutions for Interventional Prostate MRI

Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and software, and Siemens Healthcare today announced at the Radiological Society of North America (RSNA) annual meeting in Chicago, that they are collaborating on the development of a suite of innovative solutions for Interventional Prostate MRI.

30 Nov 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Sentinelle Medical's Aegis Navigation MRI and ultrasound imaging system showcased at RSNA 2009

Sentinelle Medical Inc., a leading manufacturer of MRI coils and advanced visualization software is demonstrating a number of innovative new works-in-progress, including MRI and ultrasound co-registration offering at RSNA 2009.

30 Nov 2009

Sentinelle Medical, Ultrasonix Medical announce distribution partnership for new SonixTOUCH ultrasound imaging system

Sentinelle Medical Inc., a leading manufacturer of MRI coils and advanced visualization software, and Ultrasonix Medical Corporation, a leading provider of innovative ultrasound imaging systems have announced a distribution agreement for the new SonixTOUCH Ultrasound with Aegis(TM) Navigation. The system will be shown as a work-in-progress on both Sentinelle and Ultrasonix's booths at the Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009.

30 Nov 2009

Novel initiative to improve NMR structure determination

In structural biology, the only technique available to predict the three dimensional structure of large complex molecules in solution, such as proteins and DNA, is NMR spectroscopy. To catalyze improvements in the techniques behind these predictions, the "eNMR" project has launched a new initiative. In September's Nature Methods the project issued an invitation to the entire biomolecular Nuclear Magnetic Resonance community to participate in a large scale test of modern computing algorithms.

30 Nov 2009

Exiqon announces the recognition of ICCB-L

Exiqon A/S announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence.

30 Nov 2009

Royal Philips Electronics demonstrates its portfolio of dose radiation managing products

Royal Philips Electronics today announced its response to an industry need by showing its portfolio of products designed to manage dose radiation at this year's 95th annual meeting of the Radiological Society of North America (RSNA) in Chicago.

From Philips Healthcare 30 Nov 2009

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), "Images, my way" will resonate throughout the Siemens Healthcare booth (#825) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

HPS offers recommendations against potential risks caused by radon in indoor environment

Radon is a colorless and odorless radioactive gas that is produced by the radioactive decay of radium. Radium is a product of uranium decay and is found in trace amounts naturally in nearly all rocks, soils, and groundwater as well as building materials, plants, animals, and the human body.

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

Charity urges government to stop under 18s from using sunbeds

Tomorrow Scotland takes steps to protect children from sunbeds by banning under 18s from using them and ensuring adults are fully informed of the risks, Cancer Research UK wants Westminster to bring the rest of the UK up to Scottish standards.

30 Nov 2009

Elastography decreases breast biopsies and maps tumors more precisely

Elastography is an effective, convenient technique that, when added to breast ultrasound, helps distinguish cancerous breast lesions from benign results, according to an ongoing study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Kiadis Pharma commences enrollment in multinational ATIR study

Allos Therapeutics granted U.S. patent for FOLOTYN

Micromet to present new results from its blinatumomab study at the ASH meeting

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Gentium announces financial results for the third quarter ended September 30, 2009

Presentations at Tuesday's RSNA conference

Medipattern, Sentinelle Medical sign technology access and distribution agreement

Sentinelle Medical, Siemens Healthcare to jointly develop solutions for Interventional Prostate MRI

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Sentinelle Medical's Aegis Navigation MRI and ultrasound imaging system showcased at RSNA 2009

Sentinelle Medical, Ultrasonix Medical announce distribution partnership for new SonixTOUCH ultrasound imaging system

Novel initiative to improve NMR structure determination

Exiqon announces the recognition of ICCB-L

Royal Philips Electronics demonstrates its portfolio of dose radiation managing products

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

HPS offers recommendations against potential risks caused by radon in indoor environment

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Charity urges government to stop under 18s from using sunbeds

Elastography decreases breast biopsies and maps tumors more precisely

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Cancer News and Research

Latest Cancer News and Research

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in